The importance of early cyclosporine levels in pediatric kidney transplantation. 1996

A J Matas, and K J Gillingham, and B M Chavers, and T Nevins, and C Kashtan, and S M Mauer, and W D Payne, and R Gruessner, and J S Najarian
University of Minnesota, Department of Surgery, Minneapolis 55455, USA.

We studied the impact of early cyclosporine (CSA) levels on the incidence of rejection in pediatric transplant recipients. Between 1 January 1984 and 31 December 1994, a total of 234 pediatric patients underwent kidney transplants and received CSA immunosuppression. We analyzed the impact of CSA levels (at 1 wk, 2 wk, 1 month, 2 months, and 3 months) on the incidence of rejection in the first 3 and the first 6 months post-transplant. We found that CSA levels at all timepoints correlated, i.e. recipients with low levels in the early post-transplant period tended to have low levels throughout the first 12 months. Multivariate analysis for risk factors by biopsy-proven rejection in the first 3 months revealed that the CSA trough level was the critical factor (p < 0.05). Recipients with CSA trough levels < 100 ng/ml had 2.24 times the risk of rejections vs. those with blood levels > 100 ng/ml. Similarly, the CSA trough level at 1 month was the critical risk factor for biopsy-proven rejection within the first 6 months (p < 0.05). The major risk factor for graft loss within the first 12 months was a biopsy-proven rejection episode. We conclude that in pediatric kidney transplant recipients, early CSA trough levels < 100 ng/ml are associated with a significantly increased incidence of rejection in the first 6 months post-transplant.

UI MeSH Term Description Entries
D007166 Immunosuppressive Agents Agents that suppress immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-CELLS or by inhibiting the activation of HELPER CELLS. While immunosuppression has been brought about in the past primarily to prevent rejection of transplanted organs, new applications involving mediation of the effects of INTERLEUKINS and other CYTOKINES are emerging. Immunosuppressant,Immunosuppressive Agent,Immunosuppressants,Agent, Immunosuppressive,Agents, Immunosuppressive
D007223 Infant A child between 1 and 23 months of age. Infants
D008297 Male Males
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D002675 Child, Preschool A child between the ages of 2 and 5. Children, Preschool,Preschool Child,Preschool Children
D002851 Chromatography, High Pressure Liquid Liquid chromatographic techniques which feature high inlet pressures, high sensitivity, and high speed. Chromatography, High Performance Liquid,Chromatography, High Speed Liquid,Chromatography, Liquid, High Pressure,HPLC,High Performance Liquid Chromatography,High-Performance Liquid Chromatography,UPLC,Ultra Performance Liquid Chromatography,Chromatography, High-Performance Liquid,High-Performance Liquid Chromatographies,Liquid Chromatography, High-Performance
D005260 Female Females
D005500 Follow-Up Studies Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease. Followup Studies,Follow Up Studies,Follow-Up Study,Followup Study,Studies, Follow-Up,Studies, Followup,Study, Follow-Up,Study, Followup
D006084 Graft Rejection An immune response with both cellular and humoral components, directed against an allogeneic transplant, whose tissue antigens are not compatible with those of the recipient. Transplant Rejection,Rejection, Transplant,Transplantation Rejection,Graft Rejections,Rejection, Graft,Rejection, Transplantation,Rejections, Graft,Rejections, Transplant,Rejections, Transplantation,Transplant Rejections,Transplantation Rejections
D006085 Graft Survival The survival of a graft in a host, the factors responsible for the survival and the changes occurring within the graft during growth in the host. Graft Survivals,Survival, Graft,Survivals, Graft

Related Publications

A J Matas, and K J Gillingham, and B M Chavers, and T Nevins, and C Kashtan, and S M Mauer, and W D Payne, and R Gruessner, and J S Najarian
January 1987, Advances in nephrology from the Necker Hospital,
A J Matas, and K J Gillingham, and B M Chavers, and T Nevins, and C Kashtan, and S M Mauer, and W D Payne, and R Gruessner, and J S Najarian
March 2004, Transplantation proceedings,
A J Matas, and K J Gillingham, and B M Chavers, and T Nevins, and C Kashtan, and S M Mauer, and W D Payne, and R Gruessner, and J S Najarian
January 1998, Medicinski arhiv,
A J Matas, and K J Gillingham, and B M Chavers, and T Nevins, and C Kashtan, and S M Mauer, and W D Payne, and R Gruessner, and J S Najarian
January 1998, Revista da Associacao Medica Brasileira (1992),
A J Matas, and K J Gillingham, and B M Chavers, and T Nevins, and C Kashtan, and S M Mauer, and W D Payne, and R Gruessner, and J S Najarian
January 1988, APMIS. Supplementum,
A J Matas, and K J Gillingham, and B M Chavers, and T Nevins, and C Kashtan, and S M Mauer, and W D Payne, and R Gruessner, and J S Najarian
June 1988, Transplantation proceedings,
A J Matas, and K J Gillingham, and B M Chavers, and T Nevins, and C Kashtan, and S M Mauer, and W D Payne, and R Gruessner, and J S Najarian
December 1983, Transplantation proceedings,
A J Matas, and K J Gillingham, and B M Chavers, and T Nevins, and C Kashtan, and S M Mauer, and W D Payne, and R Gruessner, and J S Najarian
February 1994, Transplantation proceedings,
A J Matas, and K J Gillingham, and B M Chavers, and T Nevins, and C Kashtan, and S M Mauer, and W D Payne, and R Gruessner, and J S Najarian
September 1987, Archives of surgery (Chicago, Ill. : 1960),
A J Matas, and K J Gillingham, and B M Chavers, and T Nevins, and C Kashtan, and S M Mauer, and W D Payne, and R Gruessner, and J S Najarian
July 2003, Aktuelle Urologie,
Copied contents to your clipboard!